Clinical trial NCT01764087: A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
Official title: An Open-label Phase I/II Study of KX2-391 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Gastric Cancer
Breast Cancer
Keywords: Stomach Neoplasms
Breast Neoplasms
Carcinoma
Neoplasms
Paclitaxel
Tubulin Modulators
Antimitotic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Pharmacologic Actions
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2013-01-09
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to determine the maximum tolerated dose (MTD) of KX2-391 in Combination with paclitaxel in Phase I, and to evaluate the efficacy of KX2-391 in combination with paclitaxel in patients who are diagnosed as gastric and breast cancer, respectively in Phase II.


Eligibility criteria: Inclusion Criteria:

Phase I Portion:

- Diagnosis of solid tumors on histopathological examination or cytological examination for which no standard of care is available or conventional treatment modalities have no therapeutic effect at the time of entering into the study

Phase II Portion:

* Diagnosis of advanced/metastatic/recurrent stomach cancer or breast cancer on histopathological examination or cytological examination for which no standard of care is available or conventional treatment modalities have no therapeutic effect at the time of entering into the study
* Subjects with stomach cancer without prior taxane therapy
* Subjects with breast cancer with prior taxane therapy
* (Optional) Providing exploratory biomarker informed consent form to obtain archival tumor tissue and/or new tumor biopsy sample

Common:

1. Based on clinical screening,

   ① If radiotherapy was given, at least 4 weeks should have passed from the last treatment date and the patient should have recovered from the toxicity (However, for limited regional radiotherapy, at least 2 weeks from the last treatment date)

   ② If hormonal therapy was given, at least 2 weeks should have passed from the last treatment date and the patient should have recovered from the toxicity.

   ③ If chemotherapy was given, at least 3 weeks should have passed from the last treatment date and the patient should have recovered from the toxicity (However, for nitrosourea or mitomycin, at least 6 weeks)
2. Aged ≥ 20 years
3. ECOG (Eastern Cooperative Oncology Group) ≤ 2
4. Life expectancy ≥ 12 weeks
5. Should meet the followings,

   ① Bone marrow function ANC (Absolute Neutrophil Count) ≥ 1.5 X 109/L, PLT (Platelet Count) ≥ 100 X 109/L, Hemoglobin ≥ 9.0 g/dl (In the case of hemoglobin of \< 9.0 g/dl, the patient can be enrolled if the value is reversed to ≥ 9.0 g/dl.)

   ② Kidney function Creatinine Clearance \> 50 ml/min or Serum Clearance ≤ 1.5 mg/dl

   ③ Liver function AST (Aspartate Aminotransferase)/ALT (Alanine Aminotransferase)/ALP (Alkaline Phosphatase) ≤ 3.0 X UNL and Total bilirubin ≤ 2.0 mg/dl (With bone metastasis, ALP ≤ 5.0 X UNL)
6. At least one measurable lesions with the length of the longest diameter of ≥ 10 mm on spiral CT or multidetector CT or ≥ 20 mm on conventional CT
7. Subjects who voluntarily consent to participate in this study and sign the written informed consent form

Exclusion Criteria:

1. Uncontrolled central nervous system metastasis
2. Malignant ascites requiring surgical treatment
3. Subjects who have blood malignancies including leukemia; or who have received or will receive bone marrow transplantation
4. Severe concurrent diseases as follows,

   ① History of unstable angina, heart failure, atrial or ventricular arrhythmia requiring pharmacological treatment, or having received treatment for myocardial infarction within 6 months (however, may be included under the judgment of the investigator if medically controlled), heart failure of Class III or IV by New York Heart Association Classes, or left ventricular ejection fraction of \< 40%

   ② Receiving therapeutic dose administration of coumarin-type anticoagulants (however, up to 2 mg daily is permitted for line opening)

   ③ Uncontrolled diabetes (fasting plasma glucose \> 2.0 X UNL), severe hypertension, thyroid disorder and active infectious disease

   ④ Psychiatric or neurological history including dementia or epilepsy which may threaten the compliance with this protocol

   ⑤ A condition not allowing oral application of tablet formulation, and any clinically significant gastrointestinal abnormalities which may interfere with taking, passing or absorption of the study drug
5. Using disallowed concomitant medications (strong CYP3A4 (Cytochrome P450 3A4) inhibitors or inducers) (When a patient is using any of the disallowed concomitant medications below, wash-out of 1 week from the medication date is required)
6. Received other investigational product within 4 weeks prior to the administration of this study drug
7. Pregnant or breast-feeding women (however, women with 12 months of natural (spontaneous) amenorrhea or surgical bilateral oophorectomy (alone or with hysterectomy) at least 6 weeks ago, with appropriate clinical profile (e.g., appropriate age, history of vasomotor symptoms), will be considered women postmenopausal and of non-childbearing potential. In the case of oophorectomy alone, a woman will be considered to be of non-childbearing potential only if her reproductive condition is confirmed by follow-up hormone level assessment)
8. History of hypersensitivity to paclitaxel, compounds with similar chemical structure, or cremophor (polyoxyethylated castor oil) ingredient
9. Neuropathy of grade ≥ 3 based on clinical screening
10. Known history of hepatitis B or C and known history of HIV serum positive
11. Others unable to participate in the study under the judgment of the investigator

Primary outcomes:
measure: Dose-limiting Toxicities (DLTs) in Phase I Portion
timeFrame: From start of the treatment to end of cycle 1, which are 4 weeks
measure: Tumor Overall Response Rates (ORRs) in Phase II Portion
timeFrame: In every 2 cycles up to end of the treatment, an expected average of 16 weeks
Secondary outcomes:
measure: Pharmacokinetic (PK) Evaluation in Phase I Portion
timeFrame: Time points at day 0, 1 and 8 in cycle 1
measure: The Preliminary Efficacy Data in Phase I Portion
timeFrame: In every 2 cycles up to end of the treatment, an expected average of 8 weeks
measure: Safety in Phase II Portion
timeFrame: From start of the treatment to end of the treatment, an expected average of 16 weeks
measure: The Efficacy Data in Phase II Portion
timeFrame: Up to die, an expected average of 24 weeks
measure: Pharmacokinetic (PK) Evaluation in Phase II Portion
timeFrame: Time points at day 1 and 8 in cycle 1
Other outcomes:
measure: Pharmacodynamic (PD) Evaluation in Phase I Portion
timeFrame: Time points at day 0 and 1 in cycle 1
measure: Exploratory Biomarker Evaluation in Phase II Portion
timeFrame: Time points at day -6 and day 0
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-Do
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Seock-Ah Im, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: